Immunology
Page 2 • 6 itemsGain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
Sanofi and Regeneron's Dupixent receives FDA approval as the first biologic treatment for pediatric chronic spontaneous urticaria in children 2-11 years old.
SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial
SAB-142 preserved C-peptide in all 4 Type 1 diabetes patients, with 3 showing super responder profiles and improved glycemic control in Phase 1 trial.
Sanofi's Tzield Receives FDA Approval for Children as Young as 1 Year to Delay Type 1 Diabetes Progression
FDA approves Sanofi's Tzield for children aged 1+ with stage 2 type 1 diabetes, marking the first disease-modifying therapy for this pediatric population.
Eupraxia Pharmaceuticals Reports Positive 36-Week Data from Highest Dose Cohort in Eosinophilic Esophagitis RESOLVE Trial
Eupraxia's highest dose cohort shows robust tissue health and symptom improvements at 36 weeks in Phase 1b/2a eosinophilic esophagitis trial.
Cigna Healthcare Adds Accord BioPharma's IMULDOSA Biosimilar to Preferred Coverage Plans
Cigna Healthcare now covers IMULDOSA (ustekinumab-srlf), Accord BioPharma's biosimilar to STELARA, under commercial plans effective April 15, 2026.
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability Over mNEXSPIKE in Phase 4 Study
Sanofi's protein-based Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in first head-to-head phase 4 study presented at ESCMID.